anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants randomized to the intervention will undergo implantation of bilateral carotid filters and OAC therapy. In addition, participants will receive additional single antiplatelet therapy with OAC for 6 months.
The present invention relates to a method for preparing micron pearl king night sour milk for assisting sleep, benefiting intestines and supplementing calcium. Raw material such as micron pearl powder, micron amber powder, micron jujube seed powder, micron pseudostellaria root powder, micron wolfberry fruit powder, micron lily root flour, royal jelly dried powder, fructo-oligosaccharide powder, intestinal tract beneficial bacteria, etc. through high-technology airflow superfine grinding processing are added into different traditional sour milk and combined and fermented into night sour milk products. The night sour milk has the obvious function of improving sleep quality and also has the effects of alloying fatigue, enhancing immunity, tranquilizing, improving eyesight, moisturizing intestines, benefiting livers, etc. Numerous insomniacs can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, and simultaneously, the night sour milk has the functions of beautifying faces, keeping youthfulness, tranquilizing and supplementing calcium because the pearl powder and the amber powder which are extolled as oriental youthfulness-keeping treasures are added. The present invention is a favorable method for preparing the night sour milk products for health care and longevity, the night sour milk has Chinese characteristics and is especially designed for middle-aged people and old people who have lack of sleep all over the world.
Corynebacterium strains for use in the prevention of a viral infection Certain enveloped RNA viruses preferably coronaviruses primarily on the nasal mucosa, then the infection develops into a severe systemic disease. The infection and its course depend on individual susceptibility. The present inventors have found that SARS-CoV-2 susceptibility is associated with differences in the overall nasal bacterial community structure. The invention utilizes among others the finding that Corynebacterium spp. has a major role in the prevention of infection and that the bacteria decrease the infection rate via multiple mechanisms. The invention is useful in the treatment and prevention of enveloped RNA virus infections in the upper respiratory tract.
NEW MATERIAL:A compound shown by the formula I (m and n are 2-10; R is OH, or lower alkoxycarbonyl; A is carboxylic acid residue of acidic anti-inflammatory agent) and its acid addition salt. EXAMPLE:1-{2-[1-( p-Chlorobenzoyl )-5-methoxy-2-methyl- 3 -indoleacetoxy]}-4-( 2- hydroxyproptyl)piperazine. USE:An anti-inflammatory agent and antiallergic. Having an inhibitory action on lipoxygenase. PREPARATION:A compound shown by the formula II is reacted with a compound shown by the formula III (X is halogen) in a solvent such as tetrahydrofuran, dioxane, etc. at room temperature - the boiling point of the solvent to give a compound shown by the formula I .
Depression in pregnancy is common, affecting up to 10% of women and represents serious risk to mother and infant. Unfortunately, antidepressant medication, a first-line treatment for depression in pregnancy, also comes with risks, making this a complex decision. Clinical care appears to be insufficient for ensuring that women make decisions that are consistent with their own values and with which they feel satisfied. Patient decision support tools can address such barriers. Canadian colleagues have created a patient decision aid (PDA) that has the potential to improve the decision-making process for women regarding antidepressant use in pregnancy in conjunction with clinical care. This study is a pilot RCT of the above PDA in London, to be conducted in parallel with a pilot RCT in Toronto.The overall objective of this project is to inform the development of a larger, international RCT to assess the efficacy of this PDA for antidepressant use in pregnancy. To achieve this objective, the investigators will assess the feasibility of the trial protocol to evaluate the PDA and determine the preliminary effect size for a larger multisite efficacy study. The primary outcome for this pilot study is the feasibility of conducting a large randomized controlled trial to evaluate the efficacy of the PDA. This includes feasibility (how well the trial protocol can be implemented), acceptability (usability and tolerability of the intervention) and adherence (the degree to which the trial protocol is followed). It is hypothesized that the protocol will be feasible, that the PDA will have a high degree of acceptability, and that adherence to the protocol will be high.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to dermatology and psychiatry, and concerns psychoemotional state correction in the patients with chronic dermatoses. That is ensured by the administration of Phrenolon 1/4 - 1/2 tablets in the morning, Amitriptyline 1/2 tablets in the afternoon and 1 tablet in the evening or every night at bedtime in the psychotic patients; therapeutic course is 1-1.5 weeks. In the neurotic patients, Phrenolon 1/2 tablets in the morning and in the evening, Amitriptyline 1/2 tablets in the afternoon and in the evening, Chlorprothixene 1/2 tablets in the evening and 1 tablet every night at bedtime; therapeutic course is 1-1,5 weeks. ^ EFFECT: method ensures the effective correction of psychoemotional state in the patients with chronic dermatoses with considering psychoemotional characteristics. ^ 2 ex
The invention comprises a process of purification of camptothecin or 11-alkoxycamptothecin according to which a mixture of one of these natural products and impurities is brought in contact with a solvent which is capable of separating from it different alkaloides as well as impurities which are hindering the hydrogenation of these compounds to respective tetrahydro analogs. Camptothecin or 11-alkoxycamptothecin is then separated from the mixture. It comprises the process of hydrogenation of on this way purified camptothecin or 11-alkoxycamptothecin to respective tetrahydro analogs where the starting material is brought in contact with hydrogen and an hydrogenation catalyst in the presence of a moderator. 11-alkoxy-1,2,6,7-tetrahydro camptothecins produced according to this process are new compounds. Further on, the invention comprises a process of oxidation of tetrahydro analogs where camptothecin or 11-alkoxytetrahydrocamptothecin is brought in contact with an oxidant in a liquid reaction medium. 10-hydroxy-11-alkoxycamptothecins obtained by this procedure are new compounds. Finally, the invention comprises the process of production of water-soluble derivatives of camptothecin substituted in the position (9) by a group having a formula -CH2R1 where R1 represents -OR2, -SR3 or -NR4R5. First, a 10-hydroxy analog is transformed to a compound with the formula CH2(NR4R5)2, then the amino group, if needed, is transformed to an -OR2 or -SR3 group. Water-soluble analogs of camptothecin represent new compounds and are useful for inhibition of cell growth of tumours sensitive to such analogs.
Selenium, zinc, copper, and manganese are essential components of antioxidant enzymes involved in the elimination of reactive oxygen species (ROS). Given that cancer cells produce high levels of ROS and the accumulation of ROS can lead to cell death, cancer cells may be susceptible to strategies that reduce ROS elimination. In this work, we prepared several artificial diets that contained normal carbohydrate, protein, and lipid levels but lacked selenium, zinc, copper, or manganese. The anticancer activity of these diets was examined in a metastatic ovarian cancer model, established by injecting ID8 Trp53-/- murine ovarian cancer cells into the peritoneal cavity of C57BL/6JRj mice. Treatments started 15 days later and consisted of replacing a normal diet with one of the artificial diets for several weeks. A significant improvement in mice survival was observed when the normal diet was replaced with the selenium-free diet. Diets lacking zinc, copper, or manganese showed no significant impact on mice survival. All diets were very well tolerated. The anticancer efficacy of a diet lacking selenium was confirmed in mice with metastatic colon cancer and in mice with metastatic triple-negative breast cancer. These results suggest that diets lacking selenium hold potential for the treatment of metastatic cancers.
The efficacy and safety of corticosteroids in the pediatric population are based on the well established course of effect of corticosteroids which is similar in pediatric and adult populations.

The adverse effects of corticosteroids in pediatric patients are similar to those in adults. [see Adverse Reactions (6)] . 

Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, IOP, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Children, who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in children than some commonly used tests of HPA axis function. The linear growth of children treated with corticosteroids by any route should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of other treatment alternatives. In order to minimize the potential growth effects of corticosteroids, children should be titrated to the lowest effective dose.
Cerebral palsy (CP) is the most common physical disability originating in childhood, occurring in 2-3 per 1,000 live births. Although the primary deficit in CP is injury to the brain, secondary impairments affecting muscle function such as weakness, contractures, and spasticity are often far more debilitating and lead to worsening disability throughout the lifespan. Some have suggested that these muscle changes in CP may be irreversible; however, it is now known that muscles are one of the most 'plastic' tissues in the body. In fact, recent evidence suggests that gross muscle hypertrophy and architectural changes within muscle fibers can occur as early as 3-5 weeks after resistance training in healthy adults. It is also unknown how effectively muscles in CP can adapt to training stimuli that target specific muscle architectural parameters, such as fascicle length and cross-sectional area. These parameters have been observed to be decreased in CP, suggesting loss of sarcomeres in-series (fiber shortening) and in-parallel (muscle atrophy). We propose here that specific training-induced muscle architectural adaptations can occur in CP, leading to improved motor function.
PROBLEM TO BE SOLVED: To prepare an ameliorating agent for constipation by including a complex of chitin and calcium therein. SOLUTION: This medicine comprises a chitin-calcium complex of chitin and an inorganic substance such as calcium. The chitin-calcium complex is derived from an exoskeleton of crustaceans, e.g. a lobster or a shrimp or a crab and is obtained by carrying out the deproteinizing treatment of the substrate derived therefrom with a dilute alkali without performing a deashing treatment while leaving the ash such as the calcium so as not to deteriorate the fibrous structure of the chitin at least twice, then washing the treatment product with water and drying the washed product. The chitin-calcium complex preferably contains 15-40% chitin and 20-35% calcium therein. The calcium contained therein contributes as a supplementary source for bones and the chitin forms the fibrous structure hardly losing the chitin in an extraction step.  Thereby, the enteric transference ratio of foods, etc., is remarkably enhanced and the agent is effective in ameliorating constipation.
The aims of the study include (1) identifying genes associated with child development and developmental delay in Taiwan (2) comparing the differences and similarities between genetic biomarkers of development and developmental delay for children in Taiwan and children from other countries (3) employing precision medicine as the method for genetic screening or test and (4) tracking children's biological, psychological and social adjustment, especially for those who have early-onset developmental delay.

The study will be completed in two phases over three years and will enroll a total of 475 0\~40-year-old participants. In the first phase, we will recruit 380 participants. Including 50 participants with typical development, 300 participants with developmental delay and 30 parents to whom have children with severe DD. Then, their genetic data will be compared with genetic data of Chang Gung Hospital and the National Center for Genome Medicine, expect to preliminary find genes associated with child language development. At the same time, 20-30 children with severe developmental delay or have family history of developmental delay will be selected as a pilot study, using whole-exome sequencing (WES) to find other genes associated with development. If the gene deficiency was found in the children, we will invite his or her parents to do WES. In the second phase, we will establish a gene panel according to the genes identified in the previous stage and recruit 95 children with developmental delay to test the gene panel prospectively. The long-term goal of this study is to establish a pioneer study for children
Objective: The COVID-19 pandemic's effects on college student mental health and its underlying mechanisms are not fully understood. Although necessary, physical distancing abruptly restricts interaction with environmental rewards and disrupts sleep patterns, both of which may contribute to psychological symptoms (eg, depression and anhedonia). This study explored differences in psychological symptoms, reward exposure and responsiveness, and sleep before versus during the pandemic. Methods: Eighty-seven college students completed baseline questionnaires and a one-week daily diary paradigm. The sample was divided into two groups based on data collection before (pre-) or after (post-COVID-19) implementation of state-wide COVID-19 physical distancing measures. Results: Findings highlight higher anhedonia, decrements in exposure to social, professional, and exercise related rewards, lower aniticipatory reward responsiveness, and lower sleep efficiency among college students during the initial months of the pandemic. Conclusions: Findings suggest anhedonia, reward system functioning, and sleep may be important targets to mitigate against college student mental health sequelae during COVID-19.
Participants first received a 0.5 mL injection of Pneumococcal vaccine (Pneumovax-23®). After a washout period of at least 6 weeks, they then received a 0.5 mL injection of Influenza vaccine (Fluarix®, GSK). After another washout period of at least 6 weeks, the participant received a 0.5 mL injection of saline (placebo).
PURPOSE:To obtain a drug composition having excellent solubility, transmucous and transcutaneous absorbability and high safety by including a scarcely soluble drug in swellable silica. CONSTITUTION:The objective drug composition can be produced by dissolving a scarcely soluble drug (e.g. hydrocortisone, barbital, cyclosporin or griseofulvin) in an organic solvent (e.g. acetone), dispersing swellable silica in the solution, thoroughly stirring the dispersion and removing the organic solvent by vacuum distillation with an evaporator, etc. Since swellable silica has a surface area of as large as 100-380m<2>/g and contains fine pores having a diameter of several tens Angstrom  between crystals, it has excellent action to disperse and immobilize a scarcely soluble drug. The solubility and dissolution speed of the scarcely soluble drug can be adjusted by varying the kind, compounding ratio, etc., of the swellable silica.
OBJECTIVE: To investigate the mechanism of endothelial cell specific molecule 1 (ESM1) promoting cervical cancer cell proliferation and EMT characteristics through zinc finger E-box binding homeobox 1 (ZEB1)/EMT pathway.
METHODS: The correlation between ESM1 expression and prognosis of cervical cancer patients was analyzed by bioinformatics. SiHa, HeLa cell lines and corresponding control cell lines with stable ESM1 expression were obtained. Cell proliferation ability was detected by CCK-8 assay. The invasion and migration ability of Hela and SiHa cells were detected by Transwell assay and scratch closure assay. Expressions of EMT-related markers E-cadherin and Vimentin were detected by real-time PCR. The ability of silenced ESM1 to tumor formation in vivo was detected by tumor formation in nude mice. The effects of aloe-emodin on inhibit ESM1 expression and its inhibitory effect on cervical cancer cells in vitro and in vivo were analyzed by the same method.
RESULTS: ESM1 was highly expressed in cervical cancer, and the high expression of ESM1 was associated with poor prognosis of cervical cancer patients. CCK-8 results showed that the proliferation, invasion and migration of Hela and SiHa cells were significantly reduced after siRNA interfered with ESM1 expression. Overexpression of ESM1 promoted the proliferation and migration of cervical cancer cells. Mechanism studies have shown that the oncogenic effect of ESM1 is realized through the ZEB1/PI3K/AKT pathway. High throughput drug screening found that aloe-emodin can target ESM1. Inhibitory effect of aloe emodin on ESM1/ZEB1/EMT signaling pathway and cervical cancer cells.
CONCLUSION: The silencing of ESM1 expression may inhibit the proliferation, invasion, metastasis and epithelial-mesenchymal transformation of cervical cancer cells by inhibiting ZEB1/PI3K/AKT. Aloe-emodin is a potential treatment for cervical cancer, which can play an anti-tumor role by inhibiting ESM1/ZEB1.
BACKGROUND: Breast density (BD) is a strong risk factor for breast cancer. Little is known about how BD develops during puberty. Understanding BD trajectories during puberty and its determinants could be crucial for promoting preventive actions against breast cancer (BC) at early ages. The objective of this research is to characterize % fibroglandular volume (%FGV), absolute fibroglandular volume (AFGV), and breast volume (BV) at different breast Tanner stages until 4-year post menarche in a Latino cohort and to assess determinants of high %FGV and AFGV during puberty and in a fully mature breast.
METHODS: This is a longitudinal follow-up of 509 girls from low-middle socioeconomic status of the Southeast area of Santiago, recruited at a mean age of 3.5 years. The inclusion criteria were singleton birth born, birthweight between 2500 and 4500 g with no medical or mental disorder. A trained dietitian measured weight and height since 3.5 years old and sexual maturation from 8 years old (breast Tanner stages and age at menarche onset). Using standardized methods, BD was measured using dual-energy X-ray absorptiometry (DXA) in various developmental periods (breast Tanner stage B1 until 4 years after menarche onset).
RESULTS: In the 509 girls, we collected 1,442 breast DXA scans; the mean age at Tanner B4 was 11.3 years. %FGV increased across breast Tanner stages and peaked 250 days after menarche. AFGV and BV peaked 2 years after menarche onset. Girls in the highest quartiles of %FGV, AFGV, and BV at Tanner B4 and B5 before menarche onset had the highest values thereafter until 4 years after menarche onset. The most important determinants of %FGV and AFGV variability were BMI z-score (R2 = 44%) and time since menarche (R2 = 42%), respectively.
CONCLUSION: We characterize the breast development during puberty, a critical window of susceptibility. Although the onset of menarche is a key milestone for breast development, we observed that girls in the highest quartiles of %FGV and AFGV tracked in that group afterwards. Following these participants in adulthood would be of interest to understand the changes in breast composition during this period and its potential link with BC risk.
Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
In pregnant rats administered 6 mg/kg/day of butoconazole nitrate intravaginally during the period of organogenesis, there was an increase in resorption rate and decrease in litter size; however, no teratogenicity was noted. This dose represents a 130- to 353-fold margin of safety based on serum levels achieved in rats following intravaginal administration compared to the serum levels achieved in humans following intravaginal administration of the recommended therapeutic dose of butoconazole nitrate.

Butoconazole nitrate has no apparent adverse effect when administered orally to pregnant rats throughout organogenesis at dose levels up to 50 mg/kg/day (5 times the human dose based on mg/m2). Daily oral doses of 100, 300 or 750 mg/kg/day (10, 30 or 75 times the human dose based on mg/m2 respectively) resulted in fetal malformations (abdominal wall defects, cleft palate), but maternal stress was also evident at these higher dose levels. There were, however, no adverse effects on litters of rabbits who received butoconazole nitrate orally, even at maternally stressful dose levels (e.g., 150 mg/kg, 24 times the human dose based on mg/m2).

Butoconazole nitrate, like other azole antifungal agents, causes dystocia in rats when treatment is extended through parturition. However, this effect was not apparent in rabbits treated with as much as 100 mg/kg/day orally (16 times the human dose based on mg/m2).

There are, however, no adequate and well-controlled studies in pregnant women. GYNAZOLE • 1® Butoconazole Nitrate Vaginal Cream USP, 2% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
BACKGROUND: Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) are widely used for tumor treatment, including metastatic colorectal cancer (mCRC). So far, there are no biomarkers that reliably predict resistance to anti-VEGF mAbs like bevacizumab. A biomarker-guided strategy for early and accurate assessment of resistance could avoid the use of non-effective treatment and improve patient outcomes. We hypothesized that repeated analysis of multiple cytokines and angiogenic growth factors (CAFs) before and during treatment using machine learning could provide an accurate and earlier, i.e., 100 days before conventional radiologic staging, prediction of resistance to first-line mCRC treatment with FOLFOX plus bevacizumab.
PATIENTS AND METHODS: 15 German and Austrian centers prospectively recruited 50 mCRC patients receiving FOLFOX plus bevacizumab as first-line treatment. Plasma samples were collected every two weeks until radiologic progression (RECIST 1.1) as determined by CT scans performed every 2 months. 102 pre-selected CAFs were centrally analyzed using a cytokine multiplex assay (Luminex, Myriad RBM).
RESULTS: Using random forests, we developed a predictive machine learning model that discriminated between the situations of "no progress within 100 days before radiological progress" and "progress within 100 days before radiological progress". We could further identify a combination of ten out of the 102 CAF markers, which fulfilled this task with 78.2% accuracy, 71.8% sensitivity, and 82.5% specificity.
CONCLUSIONS: We identified a CAF marker combination that indicates treatment resistance to FOLFOX plus bevacizumab in patients with mCRC within 100 days prior to radiologic progress.